Cargando…

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study

BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. Whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zheng, Ma, Jialin, Yao, Shuna, Yao, Zhihua, Wang, Haiying, Chu, Junfeng, Zhao, Shuang, Liu, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/
https://www.ncbi.nlm.nih.gov/pubmed/34899689
http://dx.doi.org/10.3389/fimmu.2021.727464
_version_ 1784613836669583360
author Yan, Zheng
Ma, Jialin
Yao, Shuna
Yao, Zhihua
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Liu, Yanyan
author_facet Yan, Zheng
Ma, Jialin
Yao, Shuna
Yao, Zhihua
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Liu, Yanyan
author_sort Yan, Zheng
collection PubMed
description BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients. PATIENTS AND METHODS: Patients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed. RESULTS: Seven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients. CONCLUSIONS: Low dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy.
format Online
Article
Text
id pubmed-8664390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86643902021-12-11 Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study Yan, Zheng Ma, Jialin Yao, Shuna Yao, Zhihua Wang, Haiying Chu, Junfeng Zhao, Shuang Liu, Yanyan Front Immunol Immunology BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients. PATIENTS AND METHODS: Patients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed. RESULTS: Seven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients. CONCLUSIONS: Low dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8664390/ /pubmed/34899689 http://dx.doi.org/10.3389/fimmu.2021.727464 Text en Copyright © 2021 Yan, Ma, Yao, Yao, Wang, Chu, Zhao and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yan, Zheng
Ma, Jialin
Yao, Shuna
Yao, Zhihua
Wang, Haiying
Chu, Junfeng
Zhao, Shuang
Liu, Yanyan
Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_full Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_fullStr Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_full_unstemmed Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_short Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_sort anti-angiogenic agent combined with anti-pd-1 immunotherapy showed activity in patients with classical hodgkin lymphoma who have failed immunotherapy: a retrospective case report study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/
https://www.ncbi.nlm.nih.gov/pubmed/34899689
http://dx.doi.org/10.3389/fimmu.2021.727464
work_keys_str_mv AT yanzheng antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT majialin antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT yaoshuna antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT yaozhihua antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT wanghaiying antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT chujunfeng antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT zhaoshuang antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
AT liuyanyan antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy